Cardima Appoints Dr. Peter Wong to Board of Directors - Announces Additional Board Change
FREMONT, Calif. (March 1, 2010) -- Cardima, Inc. (OTC/BB: CADM) today announced the appointment of Dr. Peter Wong to the Company’s board of directors, effective immediately. Cardima further announced that Eric Chan, PhD, has resigned his position as a board member, also effective immediately. Dr. Chan continues to serve as a consultant to the Company.
Dr. Wong is a professor at the University of British Columbia, Faculty of Medicine with a specialization in pediatric clinical neurophysiology. Dr. Wong received his training in medicine from McMaster University and completed his research fellowships at the University of California, San Diego and at Children’s Hospital Medical Center, Harvard Medical School, in Boston.
“Dr. Wong has made numerous accomplishments throughout his distinguished career,” said Tony Shum, Cardima’s Chairman. “Among these, he has developed international collaborations and conducted collaborative clinical research with a particular concentration in Asia. Through these collaborations he has developed a wide range of long-lasting and valued clinical, academic and professional contacts. We believe Dr. Wong’s experience in conducting collaborative clinical research and his extensive relationships will significantly benefit Cardima as we extend the scope of our clinical programs around the world and initiate further clinical studies. We welcome Dr. Wong to our board.”
Dr. Wong stated, “I am very excited to be joining the team at Cardima and taking on the challenge of improving the treatment of atrial fibrillation. Cardima can benefit from developing relationships with leading physicians and clinical programs in Asia and globally, and I hope to contribute to this effort.”
Mr. Shum added, “On behalf of our board and our entire company, we thank Eric Chan for his many contributions during his tenure on the Company’s board. We are pleased that he continues to provide us his technical expertise on a consulting basis.”
About Cardima
Cardima, Inc. has developed the PATHFINDER, TRACER™ and REVELATION® Series of diagnostic catheters, the VUEPORT® and NAVIPORT® Series of guiding catheters, the INTELLITEMP® Energy Management Device and the Surgical Ablation System. The Surgical Ablation Probe is intended for ablation of cardiac tissue using radio frequency (RF) energy during cardiac surgery. All of these Cardima devices have received CE mark approval and U.S. Food and Drug Administration (FDA) 510(k) clearance. The REVELATION Series of ablation catheters with the INTELLITEMP EP Energy Management Device, developed for the treatment of atrial fibrillation (AF), has received CE mark approval and is marketed in Europe.
PATHFINDER®, TRACER™, VUEPORT®, NAVIPORT®, REVELATION® and INTELLITEMP® are registered trademarks of Cardima, Inc.
Forward-Looking Statements
This press release may contain forward-looking statements. These statements are subject to risks and uncertainties. Investors are referred to the full discussion of risks and uncertainties associated with forward-looking statements as contained in our reports to the Securities and Exchange Commission, including our Forms 10-K and 10-Q. The Company assumes no obligation to update the forward-looking information.
Company Contact:
Richard Gaston M.D.
Cardima, Inc.
(510) 354-0300
www.cardima.com
Investor Contacts:
Lippert/Heilshorn & Associates
Jody Cain (jcain@lhai.com)
(310) 691-7100